FutureTech II Acquisition Corp.
FTIIU
Other OTC12.00
USD
- -
- -
CIK
0001889450
ISIN
US36119D2027
CUSIP
36119D202
Return %
Stock
S&P500
1Y
9.59
26.53
3Y
12.78
76.60
5Y
19.88
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ray Lei Chen
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 128 Gail Drive New Rochelle NY United States of America 10805
- IPO Date
- Feb 16, 2022
- CIK
- 0001889450
- Website
- futuretechii.com
- Similar Companies
- Business
- FutureTech II Acquisition Corp. is a special purpose acquisition company (SPAC) focused on acquiring and merging with businesses primarily in the technology sector, including artificial intelligence, robotic process automation, biomedical life sciences, and related technology markets. Founded in 2021 and headquartered in New Rochelle, New York, the company does not currently manufacture or sell products but facilitates business combinations through mergers, capital stock exchanges, asset acquisitions, and reorganizations. As a blank check company, FutureTech II aims to partner with high-growth technology firms to enable their transition to public entities and unlock shareholder value. The company’s core activities encompass raising capital through initial public offerings and entering into definitive business combination agreements with promising technology companies. Key recent developments include a strategic merger agreement announced in late 2024 with Longevity Biomedical, Inc., a clinical-stage biopharmaceutical firm. This transaction, expected to close in the fourth quarter of 2025 pending shareholder approval, involves FutureTech II merging into Longevity Biomedical Holdings, with Longevity Biomedical becoming the wholly owned subsidiary, creating a Nasdaq-listed biopharmaceutical entity. This expanded business scope includes therapeutic candidates across ophthalmology, cardiovascular disease, and soft tissue reconstruction, as well as a pipeline of preclinical stage indications and plans to acquire additional health-related digital technology firms. Additionally, FutureTech II finalized a significant subscription agreement in early 2025, securing capital investment to strengthen its financial position in preparation for its business combination activities. The company operates as a subsidiary of FutureTech II Partners LLC and leverages a leadership team experienced in finance, mergers and acquisitions, and corporate strategy to execute its acquisition goals. In summary, FutureTech II Acquisition Corp. primarily operates as a capital-raising and acquisition vehicle targeting technology and biomedical sectors, with its latest major move focused on merging with Longevity Biomedical to form a new publicly traded biopharmaceutical company on Nasdaq. The company remains positioned for further acquisitions and expansion within cutting-edge technology markets.